After successfully completing STTR Phase I funded design of a Marburg virus prophylactic countermeasure vaccine, Flow Pharma has received a follow-on Phase II STTR contract award to transition into vaccine manufacturing and pre-clinical testing.
Flow Pharma today announced that the Company has received a Phase II STTR contract award to continue developing a protective vaccine against Marburg virus. This award follows Flow Pharma successfully completing the Phase I STTR contract from the United States Department of Defense for the same project. Flow Pharma is working in collaboration with Dr. Trevor Brasel and his team at the University of Texas Medical Branch (UTMB) in Galveston, Texas.
“We are happy to be working with Flow Pharma on the pre-clinical testing phase of their FlowVax Marburg development program. Our team has extensive experience working with Marburg virus and similar viruses like Ebola in various pre-clinical models. We are very fortunate at UTMB in that we have access to unique BSL-4 laboratories, including the Galveston National Laboratory and the Robert E. Shope, MD, Laboratory, that allow us to conduct studies like these safely and at a high level of quality to ensure data integrity for sponsors like Flow Pharma,” said Trevor Brasel, Ph.D., M(ASCP)CM, Assistant Professor, Department of Microbiology and Immunology, UTMB.